Akebia Therapeutics (AKBA)
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Technical Analysis

1,241 Followers

Technical Sentiment

Overall Consensus
Buy
15Bullish
1Neutral
5Bearish
Technical Analysis Consensus
Sell
3Bullish
1Neutral
5Bearish
Moving Average Consensus
Strong Buy
12Bullish
0Neutral
0Bearish
Akebia Therapeutics’s (AKBA) Moving Averages Convergence Divergence (MACD) indicator is 0.09, suggesting Akebia Therapeutics is a Sell.
Akebia Therapeutics’s (AKBA) 20-Day exponential moving average is 1.22, while Akebia Therapeutics’s (AKBA) share price is $1.495, making it a Buy.
Akebia Therapeutics’s (AKBA) 50-Day exponential moving average is 1.19, while Akebia Therapeutics’s (AKBA) share price is $1.495, making it a Buy.

Akebia Therapeutics (AKBA) Pivot Points

Jul 24, 2024, 11:52 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.23
1.27
1.32
1.36
1.41
1.45
1.50
Fibonacci
1.27
1.30
1.32
1.36
1.39
1.41
1.45
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Akebia Therapeutics (AKBA) Moving Averages

Jul 24, 2024, 11:52 PM
Period
Simple
Exponential
MA5
1.39Buy
1.39Buy
MA10
1.33Buy
1.32Buy
MA20
1.14Buy
1.22Buy
MA50
1.12Buy
1.19Buy
MA100
1.33Buy
1.25Buy
MA200
1.28Buy
1.25Buy
Akebia Therapeutics’s (AKBA) 10-Day exponential moving average is 1.32, while Akebia Therapeutics’s (AKBA) share price is $1.495, making it a Buy.
Akebia Therapeutics’s (AKBA) 100-Day exponential moving average is 1.25, while Akebia Therapeutics’s (AKBA) share price is $1.495, making it a Buy.
Akebia Therapeutics’s (AKBA) stock price is $1.495 and Akebia Therapeutics’s (AKBA) 50-day simple moving average is 1.12, creating a Buy signal.
Akebia Therapeutics’s (AKBA) stock price is $1.495 and Akebia Therapeutics’s (AKBA) 100-day simple moving average is 1.33, creating a Buy signal.
Akebia Therapeutics’s (AKBA) stock price is $1.495 and Akebia Therapeutics’s (AKBA) 200-day simple moving average is 1.28, creating a Buy signal.

Akebia Therapeutics (AKBA) Technical Indicators

Jul 24, 2024, 11:52 PM
Name
Value
Implied Action
RSI (14)
72.16
Sell
STOCH (9,6)
87.48
Sell
STOCHRSI (14)
88.48
Sell
MACD (12,26)
0.09
Sell
ADX (14)
34.74
Neutral
Williams %R
0.00
-
CCI (14)
103.61
Sell
ATR (14)
0.10
-
Ultimate Oscillator
71.88
Buy
ROC
52.08
Buy
Akebia Therapeutics’s (AKBA) Relative Strength Index (RSI) is 72.16, creating a Sell signal.
Akebia Therapeutics’s (AKBA) Trend Strength Indicator (ADX) is 34.74, creating a Neutral signal.
Akebia Therapeutics’s (AKBA) Commodity Channel Index (CCI) is 103.61, creating a Sell signal.
Akebia Therapeutics’s (AKBA) Price Rate of Change (ROC) is 52.08, creating a Buy signal.

FAQ

Is AKBA a Buy, Hold, or Sell?
Based on AKBA’s technical indicators, AKBA is a Buy.
    What is AKBA’s RSI (14)?
    AKBA’s RSI (14) is 72.16, which suggests AKBA is a Sell.
      What is AKBA’s MACD?
      AKBA’s MACD is 0.09, which suggests AKBA is a Sell.
        What is AKBA’s 5-day moving average?
        AKBA’s 5-day moving average is 1.39, which suggests AKBA is a Buy.
          What is AKBA’s 20-day moving average?
          AKBA 20-day moving average is 1.14, which suggests AKBA is a Buy.
            What is AKBA’s 50-day moving average?
            AKBA’s 50-day moving average is 1.12, which suggests AKBA is a Buy.
              What is AKBA’s 200-day moving average?
              AKBA’s 200-day moving average is 1.28, which suggests AKBA is a Buy.
                What is AKBA’s Williams % R (14)?
                Currently, no data Available
                What is AKBA’s CCI (14)?
                AKBA’s CCI (14) is 103.61, which suggests AKBA is a Sell.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis